Fierce Biotech1d
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
Q4 2024 PDS Biotechnology Corp Earnings Call
Good morning and welcome to PDS Biotech's 4th quarter in full year 2024 earnings conference call. Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's 2024 results and clinical ...
Scientists map tumors for better, more precise treatments in stomach cancer
A team of Singapore scientists has made a significant discovery in understanding stomach cancer, a disease that remains one ...
Anti-Neoplastic Agents Market Report 2025: Revenues to Cross $200 Billion by 2029 due to Rising Investments in Cancer Research
Neoplastic Agents Market Report 2025" has been added to ResearchAndMarkets.com's offering.This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, ...
News-Medical.Net3d
Over 3.8 million lung cancer deaths prevented in the United States due to smoking decline
New research led by American Cancer Society (ACS) researchers estimates more than 3.8 million lung cancer deaths were averted ...
Tumor formation's two-step process: Mutated cells can persist for long periods without turning cancerous
Researchers at City of Hope have found that cell mutations are necessary but not always sufficient for tumors to form.
Genelux Corporation: Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced ...